
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics is supported by a strong revenue trajectory, with 2028E revenue raised to $732.5M and EPS improved to -$0.40, signaling better operating leverage and closer progression toward profitability. Its outlook is underpinned by durable consumables demand and recurring platform usage across Chromium, Visium, and Xenium, which should support scale as installed instruments continue to drive follow-on sales. The company also has a solid balance sheet with $523M in cash versus $84M in debt, giving it flexibility to invest in growth and absorb volatility while aligning valuation with a 7.7x 2028E EV/revenue multiple.
Bears say
10x Genomics is facing a negative outlook because the latest reported production and sales figures came in below expectations, signaling execution risk and weaker near-term operating momentum. Q2/26 consolidated AuEq production of 96,297 oz and sales of 91,646 oz missed the 105.8 koz estimate, while gold, copper, and silver output also trailed consensus as Media Luna moved through planned lower-grade, lower-recovery areas. Although 2026 guidance of 420–470 koz AuEq was reiterated, YTD output of 197,171 oz produced and 200,868 oz sold points to reliance on a second-half grade improvement, leaving the investment case dependent on a timely operational ramp and a 2026 first-ore milestone.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About 10X Genomics (TXG) Forecast
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares